Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumours
In many cases, cancer treatment depends on the use of cytotoxic drugs that cause serious adverse effects. Moreover, the percentage of patients cured with conventional chemotherapy is still low, and in the majority of cases, the disease relapses.
Colorectal and pancreatic cancers are known to be driven by Cancer Stem Cells (CSC), a class of stem-like tumour cells that are highly chemoresistant and the main drivers of cancer progression, metastasis and relapse. Therefore, targeting these cells may represent a powerful strategy to treat these tumors.
We have discovered a first-in-class compound that drastically affects the ability of Cancer Stem Cells (CSCs) to drive the growth of cancer, while maintaining a good safety profile. Our studies indicate that the compound works by disrupting the key bioenergetic pathway (called aerobic oxidative phosphorylation, or OXPHOS) of these specific cells.
Coordinator
Synthetic Chemistry
Dissemination & Exploitation manager
Technology transfer
Cancer Biology
Nano-Medicine
Pharma Technology
Regulatory Affairs
Team from CiQUS (USC) hosts Juliana Viegas from i3S for first in-person meeting within the MEDICS consortium
We are thrilled to announce the official start of the MEDiCS project, marked by a successful virtual kick-off meeting held on 19 May 2025
The European Innovation Council (EIC) has awarded €2.5 million to the MEDiCS project under its competitive 2025 EIC Transition program
By submitting this contact form, you authorize us to process your personal data.
Please note that your personal data will not be shared with or processed by third parties.